They are commonly rated as less desirable to women than people without ADHD-type symptoms. Stimulant medication does not appear to affect the rating given by women. Ratings of self worth also appear to be lower in adult men who are diagnosed with ADHD (Canu, 2007). Canus study looked at adult men with ADHD and found that they did not have higher levels of rejection sensitivity. This may be due to the possibility that individuals with ADHD may not recognize their own impairment of judgement and will overestimate their ability to interact with others to the point that they may not be aware of how poorly a social interaction may go. This may result in lower reports of rejection sensitivity.Other results of adult ADHD are higher reported incidences of traffic citations, missed workdays, and accidents. According to Fritz in a 2016 study, adult men with ADHD may be able to focus better on mental tasks after completing some type of physical exertion. This may help individuals that suffer with adult ADHD. Mood improvements were shown to be statistically significant for a short while but quickly the mood would return to pre-exertion levels. Diagnosis
While there is no single medical, physical, or genetic test for ADHD, an evaluation can be provided by a qualified mental health care professional or physician who gathers information from multiple sources.
Additional studies are being required to prove its clinical benefit. Primary biliary cholangitis
Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is an auto-immune, inflammatory liver disease which produces bile duct injury, fibrosis, cholestasis and eventual cirrhosis. It is much more common in women than men and can cause jaundice, itching (pruritus) and fatigue. Ursodeoxycholic acid therapy is beneficial, but the disease often progresses and may require liver transplantation. Animal studies suggested that treatment with FXR agonists should be beneficial in cholestatic diseases such as PBC. OCA at doses between 10 mg and 50 mg was shown to provide significant biochemical benefit, but pruritus was more frequent with higher doses. The results of a randomized, double-blind phase III study of OCA, 5 mg or 10 mg, compared to placebo (POISE) were presented in April 2014, and showed that the drug met the trials primary endpoint of a significant reduction in serum alkaline phosphatase, a biomarker predictive of disease progression, liver transplantation or death. Nonalcoholic steatohepatitis (NASH)
Non-alcoholic steatohepatitis is a common cause of abnormal liver function with histological features of fatty liver,  inflammation and fibrosis. It may progress to cirrhosis and is becoming an increasing indication for liver transplantation. It is increasing in prevalence. OCA is proposed to treat NASH.